Phase II trial of GVDexa (gemcitabine, vinorelbine and dexamethasone) regimen in relapsed/refractory Hodgkin's lymphoma.

被引：0
|
作者：
Mehra, Nikita
Ganesan, Prasanth
Jayachandran, P. K.
Joel, Anjana
Karunakaran, Parathan
Radhakrishnan, Venkatraman
Ganesan, Trivadi S.
Rathinam, Krishna
Gnana, Sagar Tenali
机构：
[1] Canc Inst WIA, Chennai, Tamil Nadu, India
[2] Jawaharlal Inst Postgrad Med Educ & Res, Pondicherry, India
[3] Christian Med Coll, Vellore, Tamil Nadu, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19519
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
    Ding, Kaiyang
    Liu, Hailing
    Ma, Jie
    Yang, Haiyan
    Cao, Lei
    Wang, Huihan
    Peng, Hongling
    Shi, Wei
    Zhao, Xiaoli
    Wu, Wei
    Zhu, Huayuan
    Li, Jianyong
    Fan, Lei
    HAEMATOLOGICA, 2023, 108 (08) : 2146 - 2154
  • [22] A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
    Fehniger, Todd A.
    Larson, Sarah
    Trinkaus, Kathryn
    Siegel, Marilyn J.
    Cashen, Amanda F.
    Blum, Kristie A.
    Fenske, Timothy S.
    Hurd, David D.
    Goy, Andre
    DiPersio, John F.
    Bartlett, Nancy L.
    BLOOD, 2009, 114 (22) : 1422 - 1422
  • [23] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [24] Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
    Mendler, J. H.
    Kelly, J.
    Voci, S.
    Marquis, D.
    Rich, L.
    Rossi, R. M.
    Bernstein, S. H.
    Jordan, C. T.
    Liesveld, J.
    Fisher, R. I.
    Friedberg, J. W.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1759 - 1764
  • [25] Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
    Michallet, Anne-Sophie
    Guillermin, Yann
    Deau, Benedicte
    Lebras, Laure
    Harel, Stephanie
    Amorin, Sandy
    Reynes, Claire
    Salles, Gilles
    Subtil, Fabien
    Brice, Pauline
    HAEMATOLOGICA, 2015, 100 (07) : E269 - E271
  • [26] Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma
    Marr, Kristin
    Ronsley, Rebecca
    Nadel, Helen
    Douglas, Kate
    Gershony, Sharon
    Strahlendorf, Caron
    Davis, Jeffrey H.
    Deyell, Rebecca J.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (04)
  • [27] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Kuruvilla, John
    Taylor, Diane
    Wang, Lisa
    Blattler, Chantale
    Keating, Armand
    Crump, Michael
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [28] A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
    Cohen, Jonathon Brett
    Wei, Lai
    Maddocks, Kami J.
    Heffner, Leonard T.
    Langston, Amelia A.
    Flowers, Christopher
    Devine, Steven M.
    Blum, Kristie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] COMPLETE RESPONSE TO IGEV (IFOSFAMIDE, GEMCITABINE AND VINORELBINE) AND OUTCOME IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Anastasia, A.
    Mazza, R.
    Giordano, L.
    Balzarotti, M.
    Magagnoli, M.
    Castagna, L.
    Spina, M.
    Tirelli, U.
    Santoro, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 37 - 37
  • [30] Gemcitabine plus rituximab therapy of patients with relapsed and refractory classical Hodgkin lymphoma.
    Younes, A
    Fayad, L
    Pro, B
    Goy, A
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    BLOOD, 2005, 106 (11) : 431A - 431A
12345